SecBot SecBot

GIKLY

Grifols SA
OTC· Pharmaceutical Preparations· CIK 0001438569 Biotech & Drug Discovery
$5.55 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $5.55
1 year
−19.0%
from $6.85 · Oct 27
30 days
−3.5%
from $5.75
52-week range
$5.06–6.85
−19% from high · low Jun 23
Avg volume 20D
10
Oct 1 spike 200
Short interest
🔒 Subscribers only
Filing reports
3
analyzed by SecBot
SecBot read MIXED 3 reports · latest
Balance 0 bearish · 0 bullish · 2 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3
Strongest MIXED Grifols reported Q1 2026 revenue of €1.7 billion (+3.3% cc, -4.8% reported), net profit up 21.9% to €73…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • TrendDOWNTREND

    1% below its 50-day average.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
May 15, 2026 SEC
Grifols filed a 6-K on May 15, 2026, calling an Ordinary General Shareholders' Meeting for June 17-18, 2026. The…
6-K — Impact 3/10
May 7, 2026 SEC
Grifols reported Q1 2026 revenue of €1.7 billion (+3.3% cc, -4.8% reported), net profit up 21.9% to €73 million, and…
6-K — Impact 5/10
Apr 17, 2026 SEC
Grifols completed a major debt refinancing in April 2026, securing $4.265 billion in new term loans and a revolving…
20-F — Impact 6/10

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q———$2.2B
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Mar 31, 2026
Clinical Trial
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Phase 2 · COMPLETED

SecBot reports

3 filings · 0 bullish · 0 bearish · 2 mixed · 1 neutral
All GIKLY filing & press-release reports (3)